Image courtesy Boston Scientific
This investment was announced just a month after the company said it was to make a further €91 million investment in R&D at its site in Galway.
The Cork investment will further the development of products – including coils, intracranial stent delivery systems and access devices – to treat neurovascular diseases of the brain, and the research laboratory infrastructure to support commercialisation.
The announcement comes a week after Pfizer, the world’s largest pharmaceutical company said it was to invest €11 million at its manufacturing process development laboratory in Cork
The Minister for Enterprise, Trade and Employment Mary Coughlan said, “This investment by Boston Scientific, a renowned global corporation and a reference life science company in Ireland, is an enormous boost of confidence in the talent at its Cork site. It further endorses Ireland’s capability to support next generation research, development and innovation at the vanguard of minimally invasive products.”
Mark Paul, President of Boston Scientific’s Neurovascular business, said, “The performance and success of our Cork site gave us the confidence that this is the correct setting and timing for this strategic investment. The Irish Government’s foresight to create centres of excellence is a cogent strategy that is attractive to industry.”
Boston Scientific employs 5,000 people in Ireland.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.